EBOVAC 2: Evaluation of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults and Children

Topic:
Ebola vaccine

Sponsor:
Janssen Vaccines & Prevention B.V.

Funder:
IMI2

Description

The purpose of EBOVAC 2 study is to assess the safety, tolerability and immunogenicity of three heterologous prime-boost regimens for Ebola vaccines Ad26.ZEBOV and MVA-BN-Filo. The study includes healthy adults and elderly participants, HIV infected participants and healthy children in 2 age strata. EBOVAC2 has been awarded a "Star of Europe" Special Prize by the French Ministry of Research in 2021. This trophy aims at rewarding and valorizing the European commitment of the research teams which have distinguished themselves by the success of their projects.

Role of EUCLID

Methodology
Statistical aspects
Data management
Global coordination of the trial

Publications

Pollard AJ, Launay O, Lelievre JD, el al; EBOVAC2 EBL2001 study group. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2021 Apr;21(4):493-506. doi: 10.1016/S1473-3099(20)30476-X. Epub 2020 Nov 17. PMID: 33217361.

Barry H, Mutua G, Kibuuka H, et al; EBL2002 Study group. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa. PLoS Med. 2021 Oct 29;18(10):e1003813. doi: 10.1371/journal.pmed.1003813. PMID: 34714820; PMCID: PMC8555783.

Similar projects